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OBJECTIVE—Hepatic steatosis is strongly associated with in-
sulin resistance, but a causal role has not been established. In
ob/ob mice, sterol regulatory element binding protein 1 (SREBP1)
mediates the induction of steatosis by upregulating target genes,
including glycerol-3-phosphate acyltransferase-1 (Gpat1), which
catalyzes the ﬁrst and committed step in the pathway of glycero-
lipid synthesis. We asked whether ob/ob mice lacking Gpat1
would have reduced hepatic steatosis and improved insulin
sensitivity.
RESEARCH DESIGN AND METHODS—Hepatic lipids, insu-
lin sensitivity, and hepatic insulin signaling were compared in
lean (Lep
/?), lean-Gpat1
/, ob/ob (Lep
ob/ob), and ob/ob-
Gpat1
/ mice.
RESULTS—Compared with ob/ob mice, the lack of Gpat1 in
ob/ob mice reduced hepatic triacylglycerol (TAG) and diacylglyc-
erol (DAG) content 59 and 74%, respectively, but increased
acyl-CoA levels. Despite the reduction in hepatic lipids, fasting
glucose and insulin concentrations did not improve, and insulin
tolerance remained impaired. In both ob/ob and ob/ob-Gpat1
/
mice, insulin resistance was accompanied by elevated hepatic
protein kinase C-ε activation and blunted insulin-stimulated Akt
activation.
CONCLUSIONS—These results suggest that decreasing he-
patic steatosis alone does not improve insulin resistance, and
that factors other than increased hepatic DAG and TAG
contribute to hepatic insulin resistance in this genetically
obese model. They also show that the SREBP1-mediated
induction of hepatic steatosis in ob/ob mice requires Gpat1.
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b/ob mice are leptin deﬁcient and become hy-
perphagic, obese, and insulin resistant (1).
Severe hepatic steatosis in ob/ob mice is sec-
ondary to hepatic upregulation of sterol regu-
latory element binding protein 1 (SREBP1) and its target
genes that increase lipogenesis and triacylglycerol (TAG)
synthesis (2). Among these target genes is Gpat1, which
encodes glycerol-3-phosphate acyltransferase-1, the mito-
chondrial enzyme that catalyzes the reaction glycerol-3-
phosphate  long-chain acyl-CoA 3 lysophosphatidic
acid, the committed step in the pathway of de novo
glycerolipid synthesis (3). Four isoforms of glycerol-3-
phosphate acyltransferase (GPAT), each encoded by a
separate gene, are able to initiate the glycerolipid synthe-
sis (4), but only Gpat1 is regulated by SREBP1 (5). GPAT1
activity and mRNA are highest in tissues with a high
capacity for TAG synthesis; in liver, the GPAT1 isoform
accounts for 30–50% of total GPAT activity. Hepatic
GPAT1 activity and mRNA abundance are increased by
insulin via activation of liver X receptor (LXR) and
SREBP1c during conditions that promote TAG synthesis
(5). Conversely, glucagon, fasting, and streptozotocin-
induced diabetes decrease liver GPAT1 mRNA and
activity (6).
Elevated hepatic TAG content in humans has been
linked to insulin resistance (7–9). In rats increasing he-
patic TAG content by adenovirus-mediated overexpres-
sion of GPAT1 induced hepatic and peripheral insulin
resistance within 5–7 days (10). Conversely, Gpat1
/
mice fed a high-fat safﬂower oil diet for 3 weeks were
protected from hepatic steatosis and insulin resistance
(11).
Although studies strongly suggest that reducing hepatic
steatosis improves hepatic insulin sensitivity (11–14), it is
unlikely that the accumulation of hepatic TAG itself,
rather than another glycerolipid metabolite such as diac-
ylglycerol (DAG), plays a causal role in impaired hepatic
insulin signaling (15). Furthermore, the role of GPAT1 in
hepatic steatosis has been questioned because both
Gpat1
/ mice fed a high-fat/high-sucrose diet for 4
months (16) and an independently derived Gpat1
/
mouse strain fed a high-fat diet for 3 months (17) devel-
oped hepatic steatosis and became insulin resistant, al-
though both developed in the context of obesity.
Because the insulin-sensitizing effects that occur when
deleted Gpat1 reduces hepatic steatosis appear to be
highly sensitive to diet composition and duration, we
investigated ob/ob mice to determine whether the absence
of Gpat1 would improve hepatic steatosis and insulin
resistance associated with genetic-induced obesity. He-
patic steatosis in ob/ob mice is associated with a 2.3-fold
increase in GPAT1 activity and a 5.5-fold increase in Gpat1
mRNA (18). Because a 5-day 90% adenovirus-mediated
knockdown of hepatic Gpat1 in ob/ob mice resulted in a
42% reduction in hepatic TAG and a 30% decrease in
plasma glucose (19), we hypothesized that a total lack of
Gpat1 in ob/ob mice would prevent both hepatic steatosis
and insulin resistance.
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Mice. Animal protocols were approved by the University of North Carolina at
Chapel Hill Institutional Animal Care and Use Committee. Mice were housed
in a pathogen-free barrier facility on a 12-h light/dark cycle with free access to
water and food (Prolab 5P76 Isopro 3000; 5.4% fat by weight). To generate
Gpat1
/ mice on an obese background, Gpat1
/ mice (20), which have been
backcrossed to C57BL/6J mice seven times, were crossed with Lep
/ob mice
(B6.V-Lep
ob/J; The Jackson Laboratory, Bar Harbor, ME). After crossing the
double heterozygotes, Lep
/ob-Gpat1
/ or Lep
/ob-Gpat1
/ mice were then
intercrossed to generate Lep
ob/ob-Gpat1
/ or Lep
ob/ob-Gpat1
/ mice and
their respective lean (Lep
/?) littermates. Male mice were used in all experi-
ments. At 16 weeks, total lean and fat mass was measured using an
EchoMRI-100 QNMR system (Echo Medical Systems, LLC, Houston, TX).
Fasted (12 h) 16-week-old mice were killed by cervical dislocation, and trunk
blood was collected. Clotted blood was centrifuged at 1,500g for 20 min and
sera were stored at 80°C until analyzed. Tissues were quickly harvested,
weighed, snap-frozen with liquid nitrogen, and stored at 80°C until analyzed.
Liver sections were ﬁxed with 4% paraformaldehyde, parafﬁn-embedded,
sectioned (0.5 m), and stained with hematoxylin-eosin.
Serum chemistries and lipids. Serum nonesteriﬁed fatty acids and total
cholesterol (Wako Diagnostics, Richmond, VA), -hydroxybutyrate (Stanbio,
Boerne, TX), and triacylglycerol and glycerol (free glycerol and triglyceride
reagents; Sigma-Aldrich, St. Louis, MO) were determined by enzymatic,
colorimetric assays. Insulin was determined by enzyme-linked immunosor-
bent assay (Rat/Mouse Insulin ELISA; Millipore, Billerica, MA).
GPAT activity. Liver tissue was homogenized in Medium I (250 mmol/l
sucrose, 10 mmol/l Tris, pH 7.4, 1 mmol/l EDTA, 1 mmol/l dithiothreitol) with
10 up-and-down strokes with a Teﬂon-glass motor-driven homogenizer. Ho-
mogenates were centrifuged at 100,000g f o r1ht oobtain total membrane
fractions. Membrane pellets were rehomogenized in Medium I. GPAT speciﬁc
activity was assayed at room temperature in a 200 l reaction mixture
containing 75 mmol/l Tris-HCl, pH 7.5, 4 mmol/l MgCl2, 1 mg/ml BSA
(essentially fatty acid–free), 1 mmol/l dithiothreitol, 8 mmol/l NaF, 800 mol/l
[
3H]glycerol 3-phosphate, and 80 mol/l palmitoyl-CoA (20). The reaction was
initiated by adding 10–30 g of membrane protein after incubating the
membrane protein on ice for 15 min in the presence or absence of 2 mmol/l
N-ethylmaleimide (NEM), which inactivates GPAT isoforms 2, 3, and 4.
NEM-resistant activity (GPAT1) was calculated by subtracting NEM-sensitive
activity from total activity.
Quantitative real-time RT-PCR. RNA was extracted from liver using Trizol
(Invitrogen, Carlsbad, CA) and reverse-transcribed with the High-Capacity
cDNA Archive kit (Applied Biosystems, Foster City, CA). cDNA was ampliﬁed
by real-time PCR in a total reaction volume of 25 l using Absolute QPCR Sybr
Green Fluorescein Mix (ThermoScientiﬁc, Waltham, MA). Primer sets are
identiﬁed in supplementary Table 1, available in an online appendix at http://
diabetes.diabetesjournals.org/content/early/2010/03/02/db09-1380/suppl/DC1.
Target gene expression was normalized to endogenous 18S rRNA and ex-
pressed as 2
ct relative to the lean-Gpat1
/ group (21).
Tissue lipid metabolites. Tissues were homogenized in 10 (wt/vol) cold
lysis buffer (20 mmol/l Tris base, 50 mmol/l NaCl, 250 mmol/l sucrose, 50
mmol/l NaF, 5 mmol/l Na4P2O710 H2O, 1% Triton X-100, and protease
inhibitors). Lipids were extracted (22), dried under N2 gas, and solubilized in
3:1:1 (vol/vol/vol) tert-butanol, methanol, and Triton X-100 (23). Tissue lipid
extracts were analyzed for TAG by an enzymatic assay (Triglyceride and
Free-Glycerol reagents; Sigma-Aldrich). Data are expressed as equivalent
triolein concentrations.
DAG and acyl-CoAs were extracted and measured by liquid chromatogra-
phy–tandem mass spectrometry (11). For ceramides, 50 mg of tissue was
homogenized with 1 ml ice-cold methanol. Chloroform (2 ml) and an internal
standard (5 nmol C17:0 ceramide; Avanti Polar Lipids, Inc., Alabaster, AL)
were added, the sample was mixed for 15 min, and water (0.6 ml) was added.
After centrifugation at 4°C, the organic layer was collected, dried overnight in
a vacuum oven, and reconstituted with chloroform.
Lipid metabolites were subjected to liquid chromatography–tandem mass
spectrometry analysis. A turbo ion spray source was interfaced with an API
3000 tandem mass spectrometer (Applied Biosystems) in conjunction with
two Perkin Elmer 200 Series micropumps and a 200 Series autosampler
(Perkin Elmer, Norwalk, CT). Total acyl-CoA, ceramide, and DAG content
were expressed as the sum of individual species.
Insulin tolerance tests. At 15 weeks of age, after an overnight (12 h) fast,
mice were injected intraperitoneally with insulin (Humulin: R; Eli Lilly,
Indianapolis, IN) at either 0.5 units/kg body wt (lean mice) or 1.5 units/kg body
wt (ob/ob mice). Glucose in tail vein blood was measured immediately before
injection (time 0) and at 15, 30, 60, 90, and 120 min after injection (One Touch
Ultra glucometer; Lifescan, Milpitas, CA). Areas of the curves were calculated
as the net area contained between individual baselines (set by the glucose
value at time 0) and curves using the trapezoidal rule (24).
Western blot analysis. Protein kinase C-ε (PKCε ) membrane translocation
was determined by immunoblotting cytosol and membrane protein extracts
(40 g) with rabbit anti-PKCε (1:100; Santa Cruz Biotechnology, Santa Cruz,
CA) (25,26). Translocation for each sample was determined as the ratio of the
density of PKCε of the membrane fraction over the density of PKCε of the
cytosolic fraction.
To evaluate insulin signaling, after an overnight (12 h) fast, insulin (2
units/kg body wt) or PBS was administered intraperitoneally to 6- or 16-week-
old mice. After 10 min, mice were killed by cervical dislocation, and livers
were excised and snap-frozen in liquid nitrogen. Tissues were homogenized in
lysis buffer (20 mmol/l Tris, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA,
50 mmol/l NaF, 2.5 mmol/l Na4P2O710 H2O, 1% Triton X-100, and Complete
Mini Protease Inhibitor Cocktail; Roche Diagnostics, Indianapolis, IN) and
centrifuged at 15,000g for 15 min. Protein (40 g) was resolved on 10%
polyacrylamide gels, transferred to nitrocellulose membranes, probed for
phosphorylated Akt (P-Akt; Thr308; 1:1,000), stripped, and reprobed for total
Akt and -tubulin (Cell Signaling Technology, Danvers, MA). Mature SREBP1
(Novus Biologicals, LLC, Littleton, CO) and phosphoenolpyruvate carboxyki-
nase (Abcam Inc., Cambridge, MA) protein expression was determined from
livers of mice fasted overnight (12 h) using the same method.
Statistical analyses. Data are expressed as least square means (LSM) 	
SEM. The main and interaction effects of the ob phenotype (lean and ob/ob)
and Gpat1 genotype (Gpat1
/ and Gpat1
/) were analyzed by two-way
ANOVA using a complete model in the general linear model (GLM) procedure
of the SAS (Version 9.2; SAS Institute, Inc., Cary, NC). Body weights over time
and insulin tolerance test curves were analyzed as repeated measures.
Comparisons of basal versus insulin-stimulated Akt expression within group
were analyzed by Student t test. Differences of P 
 0.05 were considered
signiﬁcant.
RESULTS
The absence of Gpat1 diminished hepatic steatosis
in ob/ob mice. Hepatic steatosis in ob/ob mice is medi-
ated by SREBP1c, which increases the expression of
lipogenic genes (27), including Gpat1 (5). To determine
the contribution of Gpat1 to the development of hepatic
steatosis in ob/ob mice, we intercrossed ob/ob and
Gpat1
/ mice. Compared with lean littermates, total
hepatic GPAT speciﬁc activity in ob/ob mice was 33%
higher, and both GPAT1 activity (NEM-resistant GPAT;
Fig. 1A) and mRNA expression (Fig. 1B) were 2.2-fold
higher. In ob/ob mice lacking Gpat1 (ob/ob-Gpat1
/), total
GPAT activity was reduced to levels observed in lean
mice, and GPAT1 activity was diminished. The absence of
Gpat1 induced a 28% increase in NEM-sensitive GPAT
activity (GPAT2, GPAT3, and GPAT4) in ob/ob mice (Fig.
1A). This increase in NEM-sensitive GPAT activity was
likely due to increases in both Gpat-3 and -4 expression,
although only the increase of Gpat3 mRNA expression in
ob/ob mice was signiﬁcant (supplementary Fig. 1B and C).
Collectively, the data suggest that elevated GPAT1 activity
is required for the increase in TAG accumulation in ob/ob
liver (28). Furthermore, the slight increase in activity and
message of GPAT3 and GPAT4 did not compensate for the
decrease in total GPAT activity in Gpat1
/ mice.
As previously reported (28), ob/ob mice developed
grossly steatotic livers with macrosteatosis and microste-
atosis that weighed four times more than livers from lean
littermates (Table 1) and accumulated nearly ﬁve times as
much TAG (Fig. 2A and B). In ob/ob-Gpat1
/ mice, the
lack of Gpat1 reduced liver weight by 28% and hepatic
TAG content by 59%, evidenced by the absence of large
lipid droplets. In ob/ob livers, the lipogenic genes fatty acid
synthase (Fasn) and stearoyl-CoA desaturase 1 (Scd1)
were increased 4- and 6.4-fold, respectively. However,
neither Fasn and Scd1 nor transcription factors that
regulate lipogenesis, SREBP1 (Srebf1) and ChREBP
(Mlxipl), were affected by the lack of Gpat1 (supplemen-
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form of SREBP1 was not affected by the absence of Gpat1
(supplementary Fig. 2B). The expression of genes related
to -oxidation was not altered (supplementary Fig. 2C).
Combined, these data suggest that Gpat1 appeared to be a
major SREBP1 target gene causing hepatic steatosis in
ob/ob mice.
Lack of Gpat did not protect ob/ob mice from insulin
resistance. Because an acute knockdown of Gpat1 de-
creases plasma glucose in ob/ob mice (19), we then asked
whether the elevated fasting glucose and insulin levels or
the insulin resistance that is normally observed in ob/ob
mice might be improved by a sustained decrease in hepatic
TAG. At 16 weeks of age, compared with lean mice, ob/ob
mice had 1.7- and 16.2-fold higher serum fasting glucose
and insulin concentrations, respectively (Fig. 2C and D).
The absence of Gpat1 did not reduce glucose or insulin; on
the contrary, both were higher in ob/ob-Gpat1
/ mice
than in ob/ob mice. The elevated glucose levels in the
absence of Gpat1 may be explained partly by an increase
in hepatic glucose-6-phosphate (G6pc) mRNA expression,
a key enzyme in gluconeogenesis. However, mRNA and
protein expression of phosphoenolpyruvate carboxyki-
nase was not altered (supplementary Fig. 2D and E). In
addition to not improving fasting glucose and insulin, the
absence of Gpat1 did not affect insulin sensitivity in either
lean or ob/ob mice (Fig. 2E and F).
Because hepatic steatosis and insulin resistance are
progressive disorders that likely affected multiple tissues
in 16-week-old ob/ob mice, we examined younger mice to
determine whether they might be more insulin sensitive.
At 6 weeks, livers from ob/ob mice were already steatotic
and contained 1.7-fold more hepatic TAG than livers from
lean mice (supplementary Fig. 3A). The absence of Gpat1
diminished hepatic TAG by 68 and 66% in young lean and
ob/ob mice, respectively, and effectively normalized the
content of hepatic TAG. Despite the normal hepatic TAG
content and lowered fasting glucose concentrations in
young ob/ob mice that lacked Gpat1 (supplementary Fig.
3B), serum insulin remained elevated (supplementary Fig.
3C) and insulin sensitivity remained impaired (supplemen-
tary Fig. 3D and E). These data demonstrate that early-
stage hyperinsulinemia and whole-body insulin resistance
were not improved despite a normal content of hepatic
TAG.
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FIG. 1. A: Total, NEM-resistant (NEM-R), and NEM-sensitive (NEM-S) GPAT speciﬁc activities. Liver total particulate fractions (n  3–4) were
assayed for GPAT activity in the presence or absence of 2 mmol/l NEM as described in the “RESEARCH DESIGN AND METHODS” section. B: Hepatic gene
expression of Gpat1 was determined by quantitative RT-PCR and expressed as 2
ct relative to the endogenous control 18S rRNA and the
lean-Gpat1
/ group (n  4). Lean (Lep
/?) and ob/ob (Lep
ob/ob). Data are LSM  SE. Signiﬁcant differences (P < 0.05) are denoted by different
letters. SA, speciﬁc activity.
TABLE 1
Physiologic parameters and fasting serum analytes
Lean (Lep
/?) ob/ob (Lep
ob/ob) Factors (P value)
Gpat1
/ Gpat1
/ Gpat1
/ Gpat1
/ Pheno Gpat1 Int
Physiologic parameters
Final body wt (g) 28.8 	 1.0
a 28.1 	 0.9
a 57.2 	 1.0
b 55.0 	 0.9
b 
0.001 0.133 0.407
Lean mass (% body wt) 86.3 	 0.9
a 86.3 	 1.3
a 44.5 	 0.9
b 41.9 	 1.4
b 
0.001 0.473 0.090
Fat mass (% body wt) 13.0 	 0.9
a 11.8 	 1.3
a 54.9 	 0.9
b 57.8 	 1.4
b 
0.001 0.274 0.257
Liver weight (g) 1.04 	 0.14
a 1.09 	 0.17
a 3.90 	 0.14
c 2.67 	 0.16
b 
0.001 
0.001 
0.001
Serum analytes
Nonesteriﬁed fatty acids (mmol/l) 1.03 	 0.09 0.97 	 0.09 1.17 	 0.09 1.19 	 0.1 0.056 0.826 0.672
Triacylglycerol (mmol/l) 1.04 	 0.14
ab 0.81 	 0.16
a 1.42 	 0.14
b 1.43 	 0.16
b 0.004 0.464 0.448
Glycerol (mmol/l) 0.46 	 0.06
ab 0.32 	 0.07
a 0.56 	 0.06
b 0.54 	 0.07
b 0.019 0.215 0.378
Total cholesterol (mmol/l) 3.11 	 0.39
a 2.96 	 0.39
a 6.86 	 0.39
b 5.81 	 0.39
b 
0.001 0.129 0.254
-hydroxybutyrate (mmol/l) 0.69 	 0.08
bc 0.83 	 0.07
c 0.44 	 0.07
a 0.52 	 0.08
ab 0.001 0.141 0.710
Final body weights (n  12–16) and fat and lean masses (n  6–13) were measured at 16 weeks. Serum analytes (n  4–9) were measured
from sera of mice fasted for 12 h. Values represent LSM 	 SE with signiﬁcant differences (P 
 0.05) within rows denoted by different letters.
Factors include the main effects of phenotype (Pheno; lean or ob/ob) and Gpat1 and their interaction (Int).
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Increases in the content of hepatic lipids such as DAG,
acyl-CoA, and ceramide have been proposed to mediate
hepatic insulin resistance (29,30). Compared with lean
mice, total hepatic DAG in ob/ob liver was ﬁve times higher
(Fig. 3A), and when Gpat1 was absent, DAG content
decreased to normal levels. The major DAG species re-
ﬂected this pattern, with the largest differences apparent
in C18:1-C18:1 and C18:1-C16:0 (Fig. 3B).
In Gpat1-null mice, liver acyl-CoA content is elevated
twofold because acyl-CoAs are substrates for GPAT1 (11).
Although phenotype (lean or ob/ob) did not have an effect
on total hepatic acyl-CoA content, both lean and ob/ob
livers deﬁcient in Gpat1 contained 3.3- and 5.3-fold more
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/ counterparts, respec-
tively (Fig. 3C). All the reported acyl-CoA species were
increased, but the major one affected was 18:1-CoA, with
3.8- and 6.0-fold increases in lean- and ob/ob-Gpat1
/
mice, respectively (Fig. 3D).
In addition to TAG synthesis and -oxidation, acyl-CoAs
may also be directed toward the synthesis of ceramide,
another purported modulator of insulin resistance (31).
Compared with lean mice, the content of ceramide in
livers from ob/ob mice was 25% lower (Fig. 3E), reﬂected
primarily by fewer long-chain ceramides, C22:0 and C24:0
(Fig. 3F), even though C16:0 ceramide was higher. Gpat1
deﬁciency did not signiﬁcantly affect total ceramide con-
tent, but decreased C22:0 and C24:0 ceramides by 52% in
lean mice. Thus, total ceramide content was not associ-
ated with insulin resistance in this model.
Lack of Gpat1 did not restore hepatic insulin signal-
ing in ob/ob mice. Because both DAG and TAG decreased
markedly in Gpat1-deﬁcient liver, we examined the effect
of Gpat1 deﬁciency on insulin signaling. Hepatic steatosis
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vation of PKCε and subsequent impairment of the insulin
signaling pathway (11). To determine whether the im-
proved hepatic lipid proﬁle rescued hepatic insulin signal-
ing, we examined activation of PKCε and Akt. In 16-week-
old mice, concomitant with impaired insulin sensitivity,
compared with lean mice, ob/ob mice had nearly twofold
higher hepatic PKCε activation, marked by the increased
ratio of membrane to cytosolic PKCε (Fig. 4A). Despite
having a content of hepatic DAG similar to that of lean
mice, PKCε activation was elevated in ob/ob-Gpat1
/
liver, although to a lesser extent than in ob/ob mice. At 6
weeks, no differences in hepatic PKC activation were
detected among groups (supplementary Fig. 4A). Acti-
vated PKCε binds and inactivates the insulin receptor
kinase, leading to impaired downstream insulin signaling,
such as Akt activation (32). When either 16- or 6-week-old
lean mice were stimulated with insulin, the amount of
phosphorylated Akt in liver dramatically increased com-
pared with basal expression (Fig. 4B and supplementary
Fig. 4B). In ob/ob mice, however, the response to insulin
was blunted by at least 65%, and this blunted response was
not rescued when Gpat1 was deﬁcient. These data indi-
cate that, although hepatic TAG and DAG content was
considerably lower in ob/ob-Gpat1
/ mice, hepatic insu-
lin signaling did not improve.
Lack of Gpat1 did not reduce genetic obesity. Insulin
resistance both in the liver and in peripheral tissues such
as muscle and fat can contribute to whole-body insulin
resistance. Although GPAT1 constitutes only 10% of total
GPAT activity in adipose tissue, adipose GPAT1 speciﬁc
activity is high (5), and female Gpat1
/ mice have
reduced body and gonadal adipose depot weights (20). We
determined whether the absence of Gpat1 would reduce
obesity in ob/ob mice. At 16 weeks, ob/ob mice weighed
twice as much as their lean littermates (Fig. 5A; Table 1).
However, the absence of Gpat1 in lean or ob/ob mice did
alter body weights over time or ﬁnal body weights in either
male (Fig. 5A; Table 1) or female (data not shown) mice.
Compared with lean mice, gonadal, retroperitoneal, and
inguinal white adipose and subscapular brown adipose
tissue depots weighed dramatically more in the ob/ob
mice, and were unaffected by the absence of Gpat1 (Fig.
5B). Quantitative nuclear magnetic resonance analysis
conﬁrmed that the Gpat1 deﬁciency did not have an effect
on total lean or fat mass as a percentage of body weight
(Table 1).
Lack of Gpat1 did not improve muscle lipids. Obesity-
mediated increases in muscle TAG content correlate
strongly with whole-body insulin resistance (29). Even
though GPAT1 speciﬁc activity is very low in muscle (5),
we examined lipids in muscle to determine whether
changes in muscular lipid could affect whole-body insulin
resistance. In gastrocnemius muscle, the content of TAG
and DAG in ob/ob mice was 4- and 2.3-fold higher, respec-
tively (supplementary Fig. 5A and B). The absence of
Gpat1 in lean or ob/ob mice had no effect on muscle TAG
or DAG content or on the DAG species present (supple-
mentary Fig. 5C). Muscle acyl-CoA and ceramide content
and molecular species in ob/ob mice were also unaffected
by the absence of Gpat1 (supplementary Fig. 5D–G).
The absence of Gpat1 did not alter serum lipids.
Corresponding with the development of obesity, serum
cholesterol and TAG were elevated in ob/ob mice (33),
whereas in Gpat1
/ mice, serum cholesterol is normal
and serum TAG was reduced (11). The absence of Gpat1,
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(Table 1). As reported previously in Gpat1
/ mice (16),
-hydroxybutyrate was higher in both lean and ob/ob-
Gpat1
/ mice, although this effect was not statistically
signiﬁcant.
DISCUSSION
Several studies have demonstrated that reducing hepatic
TAG content decreases hepatic insulin resistance (9,11–
14). In the liver, loss- and gain-of-function studies with
Gpat1 support a role for hepatic steatosis in the develop-
ment of insulin resistance (4). Gpat1
/ mice are pro-
tected from high-fat diet–induced hepatic steatosis and
insulin resistance (11), whereas rats that overexpress
Gpat1 in liver have increased hepatic TAG accumulation
and hepatic insulin resistance (10). Here, we show that the
absence of Gpat1 in both 6- and 16-week-old ob/ob mice
prevents severe hepatic steatosis but does not protect
against obesity-associated insulin resistance and impaired
hepatic insulin signaling.
The absence of Gpat1 reduced hepatic TAG content by
59% in ob/ob mice; however, the TAG content was still
nearly double that of livers from lean, insulin-sensitive
mice. Similarly, in ob/ob-Srebp1
/ mice, the hepatic TAG
content is less than half that of ob/ob mice, but still almost
twice that of lean mice (2). The reduced hepatic TAG
content in ob/ob-Srebp1
/ mice occurs simultaneously
with a 70% reduction of mRNA for hepatic Gpat1, a direct
target of SREBP1 (5). Like our ob/ob-Gpat1
/ mice,
despite marked decreases in hepatic steatosis, ob/ob-
Srebp1
/ mice also remain obese and insulin resistant. In
ob/ob mice, the absence of either Srebp1 or Gpat1 results
in similar decreases in hepatic TAG. Thus, GPAT1 appears
to be responsible for most of SREBP1-regulated hepatic
TAG accumulation.
Although the hepatic TAG content of 16-week-old ob/ob-
Gpat1
/ mice was similar to levels present in mice with
diet-induced insulin resistance (16,34,35), even at 6 weeks,
ob/ob-Gpat1
/ mice were hyperinsulinemic, insulin resis-
tant, and had impaired hepatic insulin signaling despite the
fact that their hepatic TAG content was lower than that of
their insulin-sensitive lean littermates. These results dem-
onstrate that in ob/ob mice, preventing hepatic steatosis
did not protect against insulin resistance, which is consis-
tent with other studies reporting a dissociation between
hepatic steatosis and insulin resistance (2,16,36–38).
Because cellular TAG is stored in lipid droplets, and
thus segregated from signaling events, it is believed that
other, perhaps related, lipid metabolites interfere with
insulin signaling pathways (15,39). Although the accumu-
lation of acyl-CoAs has been associated with insulin
resistance (40,41), mice that overexpress diacylglycerol
acyltransferase-2 in liver and high-fat–fed Gpat1
/ mice
have increased hepatic acyl-CoA content but do not de-
velop insulin resistance (11,36). Hepatic acyl-CoA content
is normal in ob/ob mice and increases when Gpat1 is
absent, but the extent of insulin resistance does not
change. Thus, in ob/ob liver, increased acyl-CoA content
itself does not impair insulin signaling. Similarly, the
absence of GPAT1 increases the content of palmitoyl-CoA,
the substrate for the ﬁrst step in ceramide biosynthesis.
However, the absence of Gpat1 did not increase hepatic
ceramide content; thus, ceramide did not contribute to
hepatic insulin resistance in this model.
DAG has been most strongly associated with insulin
resistance because it activates PKC- in the muscle (39,42)
and PKC-ε in the liver (32,43), leading to reductions in
downstream insulin signaling. Gpat1
/ mice that are
protected from safﬂower oil–induced hepatic insulin resis-
tance have reduced hepatic DAG content and PKCε acti-
vation, concomitant with improved hepatic insulin
signaling (11); conversely, rats that overexpress GPAT1 in
the liver show elevated DAG and PKCε activation coupled
with hepatic insulin resistance (10). In the current study,
however, despite normalized hepatic DAG content in
ob/ob-Gpat1
/ mice, hepatic insulin signaling remained
impaired. In this study, the decrease in DAG probably
reﬂects a reduction in lipid droplet DAG content rather
than membrane DAG (44), because activated PKCε was
unaffected. Alternatively, a signal other than DAG that is
generated during metabolic dysfunction may be responsi-
ble for PKC activation.
Studies linking reduced hepatic steatosis to improved
insulin sensitivity also report concomitant decreases in
adiposity (14,45). Because adipose mass was not dimin-
ished in the ob/ob-Gpat1
/ mice, any improvements in
either hepatic or whole-body insulin resistance due to
lower hepatic lipids could well be overshadowed by other
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Rodents deﬁcient in leptin or the leptin receptor secrete
excess corticosterone (47,48). Administering a liver-selec-
tive glucocorticoid receptor antagonist to leptin receptor–
deﬁcient rats increases glucose disposal and decreases
hepatic glucose production and fasting glucose (49), dem-
onstrating that increased glucocorticoid signaling impairs
hepatic and peripheral insulin sensitivity. Thus, it is likely
that elevated plasma glucocorticoid levels or other obesi-
ty-related factors may have prevailed over any improve-
ments in insulin sensitivity arising from an improved
hepatic lipid proﬁle in this model.
Fasting serum glucose and insulin concentrations were
21 and 48% higher, respectively, in ob/ob-Gpat1
/ mice
than in ob/ob mice despite similar insulin sensitivity.
Similarly, Gpat1
/ mice fed a high-fat/high-sucrose diet
are less glucose tolerant and have 11% higher fasting
glucose and 64% higher insulin levels than wild-type mice
(16), and ob/ob mice with a liver-speciﬁc Gpat1 knock-
down have a twofold increase in plasma insulin (19).
Hyperinsulinemia can be caused by -cell hypertrophy and
hyperplasia (50), but we did not observe differences in
islet size or number (data not shown). Even at 6 weeks,
lean and ob/ob-Gpat1
/ mice had 56 and 27% higher
fasting insulin levels, respectively, than their Gpat1
/
counterparts (supplementary Fig. 3C), suggesting that
Gpat1
/ mice are hyperinsulinemic, unrelated to the
presence of insulin resistance.
In summary, we have demonstrated that GPAT1 is
critical for the accumulation of TAG and DAG during the
development of hepatic steatosis and is a major enzyme
responsible for the lipogenic effect of SREBP1 in ob/ob
mice (2). These results suggest that decreasing hepatic
steatosis alone does not improve insulin resistance in this
genetically obese model, and that factors other than
increased hepatic DAG and TAG contribute to hepatic
insulin resistance in ob/ob mice.
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